Sandbox/00036: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 42: Line 42:
[[Category:Disease]]
[[Category:Disease]]
[[Category:Hematology]]
[[Category:Hematology]]
[[Category:Oncology]]

Latest revision as of 12:09, 28 August 2015

Template:Plasma cell neoplasm Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

Clinical presentations with immunohistochemical profile from flow cytometry and immunostaining may be utilized to differentiate plasma cell neoplasms from other diseases.

Differentiating Plasma Cell Neoplasms from Other Diseases

  • For a patient with marrow plasmacytosis, based upon the kappa (κ) and lambda (λ) expression on immunostaining or flow cytometry, the differential dignoses include:
  • Monoclonal plasma cell disorders is suggested by a markedly abnormal κ : λ ratio (>4 : 1 or <1 : 2) since plasma cells express either κ or λ.
  • Polyclonal reactive plasmacytosis is suggested by the presence of both κ-staining plasma cells and λ-staining plasma cells, usually in a κ : λ ratio of 2 : 1.
  • For a patient with monoclonal (M) proteins, the differential dignoses include: (click here for detailed criteria)[1]
  • For plasmacytoma, the differential diagnoses include:

References

  1. Kyle, R A (2009-01). "Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma". Leukemia. 23 (1): 3–9. doi:10.1038/leu.2008.291. ISSN 1476-5551. PMC 2627786. PMID 18971951. Unknown parameter |coauthors= ignored (help); Check date values in: |date= (help)